Nicotine Transdermal System Patch, 14 mg, 14 patches per box, Aveva
Recalled by AVEVA Drug Delivery Systems, Inc.
Class III — least serious
Using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).
AVEVA Drug Delivery Systems, Inc. has recalled Nicotine Transdermal System Patch, 14 mg, 14 patches per box, Aveva, according to data published by the U.S. Food and Drug Administration (FDA). The recall was reported on June 3, 2026 and was initiated on May 14, 2026. It is classified as a Class III recall, which means using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).
Below is a plain-English summary of what was recalled, why it was recalled, how to tell whether you have the affected product, and what steps you can take. For the complete and most current details, you can view the FDA record linked further down this page.
What was recalled?
This recall covers Nicotine Transdermal System Patch, 14 mg, 14 patches per box, Aveva, with approximately 59,808 pouches (4,272 Individual Folding Carton (IFC)) affected. The company behind the recall is AVEVA Drug Delivery Systems, Inc., based in Miramar, FL. The FDA describes the product as: “Nicotine Transdermal System Patch, 14 mg, 14 patches per box, Aveva, Distributed by: RUGBY LABORATORIES, Indianapolis, IN 46268, www.majorpharmaceuticals.com, NDC 0536-5895-88.”
Why was Nicotine Transdermal System Patch, 14 mg, 14 patches per box, Aveva recalled?
According to the FDA, the stated reason for the recall is: “Failed Impurities/Degradation Specifications: Elevated levels of oxidative-related impurities, exceeding shelf-life specifications during stability testing of individual units.” In plain terms, this recall relates to a chemical impurity.
This recall involves an unwanted chemical detected in the medicine — often a nitrosamine impurity, which regulators limit because long-term exposure above set levels may increase health risks. Regulators recall affected batches as a precaution. Health authorities generally advise talking to a doctor or pharmacist before stopping a prescribed medicine.
What should you do?
If you think you may have bought Nicotine Transdermal System Patch, 14 mg, 14 patches per box, Aveva, compare it against the product description and identifying codes (Lot #: 56841, Expires: 03/2028) before using it. This recall is currently listed as ongoing.
The general guidance for a matching product is to stop using it and follow the instructions in the official FDA recall notice, which may include a repair, replacement, refund, or safe disposal. When in doubt, contact AVEVA Drug Delivery Systems, Inc. or your local health authority.
About this recall
This recall was distributed in FL. RecallRadar summarizes recall information from public FDA data to make it easier to understand. We are an independent service and are not affiliated with the FDA or any government agency, so please always refer to the official source for the authoritative record — and note the “last synced” date shown on this page, since recall details can change over time.
Who this recall affects
This recall matters to anyone who bought Nicotine Transdermal System Patch, 14 mg, 14 patches per box, Aveva. Even if you feel fine, it's worth checking what you have on hand rather than assuming you were missed.
Distribution listed in the notice: Nationwide within the U.S.
What chemical impurity actually means
This recall involves an unwanted chemical detected in the medicine — often a nitrosamine impurity, which regulators limit because long-term exposure above set levels may increase health risks. Regulators recall affected batches as a precaution. Health authorities generally advise talking to a doctor or pharmacist before stopping a prescribed medicine.
In this case, the concern applies specifically to Nicotine Transdermal System Patch, 14 mg, 14 patches per box, Aveva from AVEVA Drug Delivery Systems, Inc. — not to the wider category of products. Similar items from other brands aren't part of this recall.
How to check whether you have it
On medicine bottles, the lot number and expiration date are printed on the pharmacy label or stamped directly on the manufacturer's bottle — often near the bottom edge or on the back. If a pharmacy label covers it, your pharmacist can look up the lot they dispensed.
Compare what you find against the identifying details in this recall: Lot #: 56841, Expires: 03/2028
What to do if you already bought it
Do not stop taking a prescribed medicine on your own because of a recall — for many conditions, an interrupted dose carries its own risk.
Instead, check the lot number against the details above and contact your pharmacist, who can confirm what they dispensed and arrange a replacement.
If you've had an unexpected reaction, contact your healthcare provider. Problems can also be reported to the FDA's MedWatch program.
Full recall details
- Status
- Ongoing
- Date reported
- June 3, 2026
- Recall started
- May 14, 2026
- Distributed in
- FL
What you can do
Check whether any product you have matches the description and codes above. If it does, stop using it and follow the instructions in the official recall notice. When in doubt, contact the company or your local health authority.
Quick answers
Why was Nicotine Transdermal System Patch, 14 mg, 14 patches per box, Aveva recalled?+
According to the FDA: Failed Impurities/Degradation Specifications: Elevated levels of oxidative-related impurities, ex…
How serious is this recall?+
Class III — least serious. Using this product is not likely to cause health problems, but it breaks an FDA rule (for example, a labeling or packaging issue).
What should I do if I have Nicotine Transdermal System Patch, 14 mg, 14 patches per box, Aveva?+
Compare your product against the description and identifying codes on this page. If it matches, stop using it and follow the instructions in the official recall notice — this usually means returning it for a refund or discarding it. When in doubt, contact the company or your local health authority.
Opens the U.S. Food and Drug Administration (FDA) data for this recall.
Recall number: D-0550-2026. Information last synced from the FDA on August 20, 2026.